Pamela Crilley, DO, explains the benefits and downfalls of prescribing tyrosine kinase inhibitors for the treatment of CML.
Interviews
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Fast Track Designation to TRE-515 for KRAS G12C NSCLC
2
Pirtobrutinib Gains FDA Approval for Frontline CLL/SLL in Select Patients
3
NDA Submission Initiated for Zipalertinib Combo in EGFR Exon 20+ NSCLC
4
Ubamatamab Shows Durable Responses in Low-Grade Serous Ovarian Cancer
5